KINNATE BIOPHARMA INC (KNTE) Stock Analyst Ratings
USA - NASDAQ:KNTE - US49705R1059 - Common Stock
2.65 USD
-0.01 (-0.38%)
2.65 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 78% to KNTE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 2.41. This target is -9.04% below the current price.
KNTE was analyzed by 10 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about KNTE.
In the previous month the buy percentage consensus was at a similar level.
KNTE was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-02-26 | Stifel | Maintains | Hold -> Hold |
| 2024-01-17 | Wedbush | Reiterate | Neutral -> Neutral |
| 2023-09-19 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-09-19 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-09-19 | Jefferies | Maintains | Buy -> Buy |
| 2023-09-19 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-12 | Stifel | Maintains | Hold -> Hold |
| 2023-05-12 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-04-20 | HC Wainwright & Co. | Maintains | Buy |
| 2023-04-19 | Goldman Sachs | Maintains | Buy |
| 2023-04-18 | Goldman Sachs | Maintains | Buy |
| 2023-03-20 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-16 | Stifel | Maintains | Hold |
| 2023-03-16 | Wedbush | Maintains | Outperform |
| 2022-11-17 | Stifel | Downgrade | Buy -> Hold |
| 2022-07-28 | HC Wainwright & Co. | Initiate | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2022-05-19 | Piper Sandler | Maintains | Overweight |
| 2021-09-27 | Jefferies | Initiate | Buy |
| 2021-09-23 | Stifel | Initiate | Buy |
| 2021-07-13 | William Blair | Initiate | Outperform |
KINNATE BIOPHARMA INC / KNTE FAQ
What is the average price target for KINNATE BIOPHARMA INC (KNTE) stock?
10 analysts have analysed KNTE and the average price target is 2.41 USD. This implies a price decrease of -9.04% is expected in the next year compared to the current price of 2.65.
How do analysts rate KINNATE BIOPHARMA INC (KNTE)?
The consensus rating for KINNATE BIOPHARMA INC (KNTE) is 78 / 100 . This indicates that analysts generally have a positive outlook on the stock.